Oncocytic metaplasia rarely has been reported in mucoepidermoid carcinomas. Most salivary gland lesions with oncocytic change are benign; therefore, it is important to distinguish mucoepidermoid carcinoma from other entities that may show prominent oncocytic change. We report a rare case of oncocytic mucoepidermoid carcinoma in a 65-year-old woman.
Introduction
Oncocytic lesions of the salivary glands include oncocytosis, oncocytoma, and oncocytic carcinoma. The oncocytic changes can be prominent features of a Warthin tumor, pleomorphic adenoma, or acinic cell carcinoma. Less frequently, mucoepidermoid carcinomas (MECs) exhibit prominent oncocytic change. 1 The parotid gland is the most common location of MEC. A review of the English-language literature shows only 36 cases of oncocytic mucoepidermoid carcinoma (OMEC) involving the parotid gland (table 1). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Making the distinction between OMEC and benign lesions that mimic it is necessary for appropriate treatment. We herein report an interesting case of OMEC. Important histopathologic differential diagnoses are discussed, along with a review of the literature.
Case report
A 65-year-old woman presented with a painless, firm to hard, slowly growing mass in the right parotid region of 6 months' duration. Fine-needle aspiration cytology (FNAC) showed predominant clusters of oncocytic cells. Based on that, a diagnosis of oncocytoma was made. Consequently, a superficial parotidectomy was done. Grossly, a vague nodule was identified within the gland parenchyma, measuring 1 cm in diameter. The cut surface of the nodule was grayish brown and slightly mucoid.
Histologic examination revealed a circumscribed but unencapsulated tumor that was partly cystic. At its periphery, the tumor showed nests and sheets of oncocytic cells (figure 1, A). The center of the tumor was cystic ( figure 1, B) . Epidermoid cells and a few mucuscontaining cells were identified on the inner side of the oncocytic nests, as well as a few dispersed within the main mass of oncocytes (figure 1, C). Mucinous cyst formation and foci of extravasated mucin were observed. Areas of necrosis were present (figure 1, D).
Fibrous stroma and inflammatory infiltrate were present at the periphery of the tumor. Surrounding salivary gland parenchyma appeared unremarkable, and resection margins were free of tumor. No lymphovascular invasion or increase in mitotic figures was recognized. Mucin stains highlighted the presence of mucous cells (figure 2, A); p63 immunostain displayed diffuse and strong positivity in the squamous areas ( figure 2, B ).
In view of these findings, a diagnosis of an oncocytic variant of MEC of the parotid gland was established. The patient had no evidence of disease at follow-up 12 months after the diagnosis.
Discussion
MEC is the most common malignant salivary gland tumor. 2 It is typically composed of epidermoid cells, intermediate cells, and mucus-producing cells in varying proportions. Rarely, oncocytic cells predominate and give rise to various diagnostic possibilities. A review of the literature revealed that the parotid gland is the most commonly encountered site. [8] [9] [10] [11] [12] Less commonly, submandibular, sublingual, lacrimal, bronchial, and tracheal glands are involved. [12] [13] [14] [15] There is a slight male preponderance for this lesion; ages in the reports ranged from 9 to 85 years, with a mean of 58.48 years (table 1).
Mo s t p a r o t i d
OMECs histologically fall into low-or intermediate-grade lesions. Follow-up described in the literature ranged from 2 months to 10 years with no evidence of disease. Early recurrence was seen in 1 case 8 months after diagnosis. 5 One of the reported cases recurred late, 59 months after excision. 10 One of these 2 patients was found to have high-grade tumors on histopathology. 5, 10 None of the patients with reported follow-up findings have shown lymph node or distant metastases or death due to the disease. Previously reported cases of OMEC have been graded with various methods, including Armed Forces Institute of Pathology (AFIP) and Brandwein grading systems. 16, 17 Interestingly, the histologic grade of these tumors did not appear to aid in determining their prognosis. Our case fell into the intermediate grade and grade II, respectively, of the AFIP and Brandwein grading systems because of the presence of necrosis, focal cystic change, and rare mucinous cells.
The distinction of OMEC from other oncocytic and oncocytoid tumors is challenging when areas of typical MEC are sparse within the tumor. Notably, most cases of OMEC have a predominant oncocytic component (>50 to 90%), although the per- Previous cases suggest that p63 may be a useful marker to help distinguish between OMEC and its imitators. 1 Staining with p63 has been seen in the epidermoid component of typical MECs; p63 may be useful for identifying squamous/epidermoid components in OMEC, especially when the epidermoid component is sparse or scant. Pure oncocytomas and oncocytic carcinomas show a peripheral staining pattern. Squamous cell carcinoma and myoepitheliomas/myoepithelial carcinomas are usually also strongly and diffusely positive for p63. However, squamous cell carcinomas and myoepitheliomas lack mucin-producing cells.
Myoepithelial tumors with oncocytic features will also stain for other myoepithelial markers, such as calponin and actin. Oncocytic cystadenomas are p63-negative. Benign tumors, such as pleomorphic adenoma and Warthin tumor, have myxoid/chondroid stroma and an absence of mucous cells, respectively.
In some cases, a history of local trauma, usually in the form of a prior FNAC biopsy, may produce squamous metaplasia in a case of an otherwise oncocytic tumor. However, the presence of mucous cells and the pattern of p63 staining are helpful in establishing the diagnosis of OMEC. In the present case, FNAC was performed before the surgery; however, the necrosis and the epidermoid component were far more than could be explained by prior trauma. Moreover, the presence of mucous cells excluded the possibility of secondary metaplasia.
The aim of this article is to familiarize pathologists and clinicians with this rare entity. OMEC mostly mimics benign tumors; therefore, its identification becomes clinically important because of vast difference in their prognosis. The weakness of the article is that it reports only a single case without long-term follow-up. More cases need to be reported in the literature to better understand OMECs' clinical behavior.
In conclusion, OMEC is a rare variant of MEC. Awareness of this entity and knowledge of salient features that will exclude other benign oncocytic lesions, especially oncocytoma, are important for their prognostic significance.
